Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I mass balance and pharmacokinetics study of [14C]DS-1001b in healthy adult Japanese men
jRCT2071240033Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of safusidenib, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Mass balance and Pharmacokinetics. Started Aug 2024; status: completed.
02
Drugs
safusidenib
Beyond the preview
Go deeper on jRCT2071240033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240033.